Sino Biopharm to present 45 research results at ASCO

Sino Biopharmaceutical Limited announced that it will present 45 latest research results at the 2025 ASCO Annual Meeting. These include 12 oral sessions, with 4 designated as Late-Breaking Abstracts. Key presentations will cover a range of oncological advancements, including novel treatments for lung cancer, soft tissue sarcoma, glioblastoma, and endometrial cancer. Notable studies include CAMPASS (Abstract LBA8502), investigating Benmelstobart in combination with anlotinib versus pembrolizumab for advanced non-small cell lung cancer, and R-ALPS (Abstract LBA8004), a phase III trial of TQB2450 with or without anlotinib for NSCLC. The company’s diverse research portfolio spans digestive system tumors, breast cancers, gynecologic cancers, and urinary system cancers.